TTGassociations Publications January 2019 - Page 14

Chan takes on speaker duties China Pharmaceutical Innovation and Research Development Association joined IFPMA and I flew to the capital and as- sisted it by reviewing its first draft of the code with other members. What’s the biggest challenge in the work that you do for HKAPI? It’s how to align different members’ de- mands and thinking (with our goals and activities). We have adopted various meth- ods to obtain members’ thoughts, such having our CEO to meet with the general managers of member companies to seek their views. Prior to that, we conducted member surveys. We adopt an evidence-based discussion approach and we carry out a lot of surveys and research. As such, coordination and support from members is vital. When developing systems, I need to balance societal benefits with compli- ance clauses. I am fortunate to have the support of the Board of Directors. Our members treat me well too. No matter how different the Board’s view is during discussion, we must unani- mously align with the outcome. I am also very proud of our high ethical standards and compliance to the Code of Practice. For years we have worked very hard on this for the industry because if one member were to breach the code, it would be a loss for the whole industry. HKAPI marked its 50 th anniversary in 2018. What’s your vision for the next 50 years? We hope to help Hong Kong citizens expediently use innovative and effective healthcare solutions, and to continue to foster professional development to fuel industry growth. Undoubtedly, our ongoing responsibil- ity is to leverage the experience we gain from different places and multinational companies, and share best practices with our members to improve our medical system. This is our dedication and explains why many position papers have been submit- ted over the last decade. One cannot imagine why a small office of six people would drive so many qualitative research and surveys. Some of these surveys are not one-off, rather they are question- naires sent out regularly to monitor the effectiveness of a particular system. Tell me more about HKAPI’s efforts on professional development. HKAPI is a platform equipped with different forms of training for members because of good submission practice and good review practice. High ethical stand- ard is our cornerstone. We conduct systematic educational programmes such as a 22-week course for nominated medical representa- tives from member companies. We also conduct regulatory training programmes such as the one implemented with the University of Hong Kong (HKU). HKU students are welcome to participate for free to gain professional knowledge outside of their syllabus. As well, our ongoing Code of Practice workshop takes place at least once a year, drawing about 120 participants. All these are in addition to our patients’ workshops and trainer training sessions. On the academic front, we support HKU and Macau University each year by staging a seminar to exchange intel- ligence on healthcare systems or special topics involving the two cities. Our semi- nar this year focused on public-private partnership in the healthcare system. And finally, we have the Patient Empowerment Forum which is organised annually with the Hospital Authority and Hong Kong Alliance for Patient Organiza- tions. It is now in its fifth year, and the 2018 edition covered topics like diabetes, medical device, digital device, medicine and home care. The event promotes exchange among stakeholders, academic members and even governments. A champion for ethical standards Prior to joining the pharmaceutical indus- try, Sabrina Chan was with the External Affairs Department of i-CABLE Commu- nications, tackling government relations, regulatory issues, corporate affairs, and the promotion of the company’s core products and services. She co-founded the Telecommunica- tions Research Project under the Centre of Asia Studies (University of Hong Kong, HKU), and was a journalist for various print and electronic media outlets. Chan studied communications in Hong Kong when she began her tertiary education. She holds a graduate degree in International Studies from the University of Sheffield (UK), as well as law degrees from the Chinese University of Hong Kong (CUHK) and University of Tsinghua (China). She is a member of the High Level Steering Committee on Antimicrobial Resistance and of the Business Facilitation Advisory Committee in Hong Kong. Other career achievements include: • A close partnership with universi- ties in the roles of Chair of Advisory Board of the HKU Bachelor of Phar- macy Programme, and as Adjunct Assistant Professor of CUHK School of Pharmacy • A long-time member of the Working Committee to develop strategies for promulgating Codes of Practice across APEC economies • A mentor with APEC and IFPMA programmes, where she shared best practices through training work- shops and panel discussions at vari- ous forums attended by delegates from APEC member economies and biopharmaceutical sector experts